Skip to main content

GenMark and Roche Tie the Knot as Roche Jumps Into Diagnostics

Publish date:
Video Duration:

GenMark  (GNMK)  shares took off on Monday after Roche Diagnostics said it will pay $1.8 billion in cash for the company, making molecular diagnostic testing a part of the Swiss-based pharmaceutical giant's broader offerings.

Roche said it will pay $24.05 a share in cash for each GenMark share, representing a premium of 43% on GenMark’s closing share price on Feb. 10, before media speculation about a deal.

Carlsbad, California-based GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sample. The company last March received U.S. Food and Drug Administration emergency-use authorization for its rapid COVID-19 test called ePlex.

Latest Videos From TheStreet and Jim Cramer:

Related Videos